Why MedTech Founders Are Running Clinical Trials in New Zealand

New Zealand does not get mentioned often in conversations about clinical trial strategy. The United States typically dominates the conversation, Australia gets a regular look-in, and Europe is the default for sponsors who need ICH-aligned data. New Zealand tends to sit quietly in the background.

But this is starting to change. For MedTech founders running early-phase studies, proof-of-concept trials, or first-in-human work, New Zealand offers a regulatory environment and cost structure that most other jurisdictions cannot match. The challenge is that not many founders know this until they have already spent more time and money elsewhere.

Why is New Zealand worth considering for clinical trials?

The short answer is speed and cost. Trials in New Zealand routinely reach first-patient-in within four to six weeks of submission. The equivalent timeline in the United States or Europe is commonly measured in months.

The cost advantage is equally significant. Trials in New Zealand are typically 30 to 50 percent more cost-effective than equivalent studies run in the US or Europe. The savings come from competitive per-patient costs, lower investigator and clinical research associate salaries, favourable exchange rates against the US dollar, and a government-backed 15 percent R&D tax credit on qualifying research expenditure.

For an early-stage MedTech company managing runway carefully, that differential can extend the life of a funding round, reduce the amount required in the next raise, or simply allow more patients to be enrolled within the same budget.

How does the approval process work, and what makes it different for devices?

Two bodies govern clinical trial approval in New Zealand: Medsafe, the Medicines and Medical Devices Safety Authority, and the Health and Disability Ethics Committees (HDEC). Crucially, both reviews run in parallel, so sponsors are not waiting on one before beginning the other. HDEC approvals for well-prepared submissions average three to four weeks. Medsafe typically takes around six weeks. The total start-up timeline of four to six weeks is a documented norm, not an optimistic estimate.

New Zealand also does not require a US-style Investigational New Drug (IND) application, and investigational products shipped from the US do not need FDA export approval. This removes a layer of preparation that catches many sponsors off guard.

For medical device companies specifically, the pathway is even lighter. Device-only trials do not fall under the Medicines Act approval pathway, meaning there is no Section 30 Medsafe approval required. HDEC ethics approval still applies, and Medsafe asks to be informed by email, but the formal regulatory burden is significantly reduced. For combination products, where a device delivers or monitors a drug, the picture is more nuanced and worth discussing with a regulatory specialist early.

Is the data accepted internationally?

Yes. New Zealand runs all clinical trials under ICH-GCP standards, aligned with the European Medicines Agency guideline. Data generated in New Zealand is accepted by the FDA, the TGA in Australia, the EMA, and other major regulatory bodies. Running a trial here does not create a parallel dataset that needs to be repeated elsewhere.

New Zealand also integrates routinely with Australian and Asia-Pacific sites in multiregional trials. Sponsors who begin in New Zealand often extend into Australia without rebuilding their regulatory infrastructure, given the significant alignment between Medsafe and the TGA.

What should MedTech founders do next?

Navigating New Zealand's clinical trial environment efficiently requires knowing where the nuances sit, particularly for combination products, device trials, and programs that will eventually expand into Australia or other Asia-Pacific markets.

Arcadia works with MedTech companies on regulatory and market access strategy across Australia and New Zealand. If you are planning a clinical program and want to understand whether New Zealand belongs in that plan, we would welcome the conversation.

If you're planning a clinical program and want to understand whether New Zealand belongs in that plan, contact Arcadia to start the conversation.